Star Therapeutics Raises $200M After Vega Sale to Incyte

Selling a late-stage drug program can leave the company that created it working earlier in development again. Star Therapeutics has reached that unusual position after transferring Vega Therapeutics to Incyte, with a new financing supporting the next set of scientific decisions in South San Francisco.

Star announced a $200M private financing on October 23, 2026, co-led by OrbiMed and Janus Henderson Investors. The company plans to advance preclinical programs into clinical development and add programs to its pipeline, extending an antibody-discovery effort whose best-known recent clinical asset now has a different owner.

What Star is financing after the Vega sale

The financing follows Incyte's July acquisition of Vega, formerly a wholly owned Star subsidiary. That sequence matters to the investment story: the new capital supports Star's next pipeline, while the advanced program that helped establish its recent record continues elsewhere. Reading an older description of Star as a late-stage biotech can obscure the work being financed today.

The October announcement identifies the new transaction as a private financing, without assigning a conventional Series E or other letter. Its investors include Agent Capital, Catalio Capital Management, Cormorant Asset Management, New Leaf Venture Partners, NYBC Ventures, RA Capital Management, Redmile, Sofinnova Investments and Soleus Capital, alongside an unnamed sovereign wealth fund. The announcement leaves the company's valuation and the identities of its retained preclinical programs undisclosed.

Those omissions set the useful boundary for interpreting the round. Investors are backing the organization's ability to develop additional candidates before outsiders can inspect a named set of clinical results from those programs. The capital gives Star resources to pursue that work; its eventual clinical evidence will emerge from the individual molecules selected for development.

That makes the operating story more interesting than a simple progression from one financing letter to the next. A company can have an experienced drug-development team, a completed subsidiary sale and a comparatively early retained pipeline at the same moment. Each describes a different part of the business.

The antibody moved to Incyte

Incyte completed the Vega acquisition on July 6, 2026, adding VGA039, also called latarcibart, to its hematology portfolio. The investigational monoclonal antibody was in Phase 3 development for von Willebrand disease, an inherited bleeding disorder. Incyte described a potential once-monthly, subcutaneous preventive treatment, with clinical development and regulatory review still ahead.

VGA039 targets protein S, with the aim of improving the body's ability to control bleeding. Its appeal reaches beyond the molecular description: the proposed administration schedule would change the treatment burden relative to frequent intravenous infusions. That potential helps explain why a pharmaceutical company with a hematology business would want to take responsibility for the next stages of development.

The purchase terms also need careful accounting. Incyte paid $1.25B upfront, with Star eligible for up to $750M in additional payments tied to sales milestones. The frequently cited maximum value of $2B includes those contingent payments. It should stay separate from the $200M financing and from any estimate of Star's current cash, which the financing announcement does not establish.

For Star's remaining researchers, the sale changes which experiments belong inside their company's immediate pipeline. For Incyte, the transaction adds a specific late-stage asset and its development obligations. The same antibody therefore sits inside two different corporate stories: a completed transfer for its originator and an ongoing clinical program for its buyer.

The discovery experience stays with the team

Star was founded in 2018, and its current leadership page identifies Adam Rosenthal as founder, CEO and board chair. Sandip Panicker is co-founder and CSO, with Scott Robertson serving as CBO and CFO. Their roles connect the scientific work of selecting a target with the financing and business decisions needed to keep a development program moving.

Panicker previously led discovery biology at True North Therapeutics, where his work contributed to the discovery of Enjaymo, the approved treatment for cold agglutinin disease. Rosenthal's earlier operating experience includes True North and iPierian. That history gives investors something concrete to examine when the next programs remain undisclosed, while leaving each new candidate's scientific prospects to be established on its own evidence.

Star describes its research approach in terms of novel targets, antibody development, and expertise in hematology and immunology. The company also describes natural-history studies and collaboration with patient-advocacy organizations as ways to understand diseases where the course of illness and unmet need may be poorly documented. Understanding what patients experience helps frame what an investigational therapy would need to accomplish.

The organizational advantage being financed is the ability to repeat that work across programs. A subsidiary sale transfers a business and its assets, but the next investment decision also considers the scientific and operating experience available for the remaining effort. Star's new pipeline will give that experience another set of problems to solve.

A returning investor faces a changed portfolio

Janus Henderson also participated in Star's $125M Series D in September 2025, co-led by Sanofi Ventures and Viking Global Investors. At that point, the financing supported the clinical advancement of VGA039. Returning to the company after Vega's sale means evaluating a different collection of development work under the same corporate name.

For biotechnology founders, that distinction affects how a financing should be explained. A historical clinical milestone can demonstrate what a team has accomplished without describing the maturity of the assets it currently owns. Investors, prospective partners and recruits need to know which part of the record travels forward as experience and which part now belongs to somebody else's pipeline.

Star's announcement commits the new proceeds to moving preclinical programs toward the clinic and expanding the pipeline. It supplies no public schedule for those transitions, and it leaves individual targets unnamed. The useful developments to follow are therefore program disclosures and clinical entry, rather than an assumed timeline inferred from the size of the financing.

At Star, the next company story will take shape through those selections: which biological problems the team pursues, which antibodies advance, and what the first clinical observations reveal. Vega continues with Incyte while Rosenthal, Panicker and their colleagues work toward introducing the programs that will define Star's next pipeline.